Ensol Biosciences Inc. (XKON: 140610)
South Korea
· Delayed Price · Currency is KRW
6,220.00
-240.00 (-3.72%)
Sep 10, 2024, 9:00 AM KST
Ensol Biosciences Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
| TTM
| FY 2017 | FY 2016 | FY 2015 |
| Dec '17 Dec 31, 2017 | Dec '17 Dec 31, 2017 | Dec '16 Dec 31, 2016 | Dec '15 Dec 31, 2015 |
| Operating Revenue | 537.46 | 537.46 | 173.97 | 201.99 |
| Other Revenue | - | - | -0 | - |
| Revenue | 537.46 | 537.46 | 173.97 | 201.99 |
| Revenue Growth (YoY) | - | 208.94% | -13.87% | - |
| Cost of Revenue | 384.42 | 384.42 | 203.03 | 218.58 |
| Gross Profit | 153.05 | 153.05 | -29.06 | -16.59 |
| Selling, General & Admin | 1,795 | 1,795 | 1,897 | 1,026 |
| Research & Development | 2,889 | 2,889 | 2,478 | 983.09 |
| Other Operating Expenses | 49.29 | 49.29 | 36.86 | 28.11 |
| Operating Expenses | 5,318 | 5,318 | 4,654 | 2,238 |
| Operating Income | -5,165 | -5,165 | -4,683 | -2,255 |
| Interest Expense | -2.03 | -2.03 | -38.05 | -834.57 |
| Interest & Investment Income | 35.26 | 35.26 | 78.53 | 54.58 |
| Other Non Operating Income (Expenses) | 40.11 | 40.11 | 54.91 | -3,073 |
| EBT Excluding Unusual Items | -5,092 | -5,092 | -4,588 | -6,108 |
| Impairment of Goodwill | - | - | -1,480 | - |
| Gain (Loss) on Sale of Investments | - | - | - | -19.93 |
| Gain (Loss) on Sale of Assets | 1.48 | 1.48 | - | - |
| Asset Writedown | -313.2 | -313.2 | - | - |
| Pretax Income | -5,404 | -5,404 | -6,067 | -6,128 |
| Net Income | -5,404 | -5,404 | -6,067 | -6,128 |
| Net Income to Common | -5,404 | -5,404 | -6,067 | -6,128 |
| Shares Outstanding (Basic) | 8 | 8 | 8 | 7 |
| Shares Outstanding (Diluted) | 8 | 8 | 8 | 7 |
| Shares Change (YoY) | - | 1.79% | 22.68% | - |
| EPS (Basic) | -644.00 | -644.00 | -736.00 | -912.00 |
| EPS (Diluted) | -644.00 | -644.00 | -736.00 | -912.00 |
| Free Cash Flow | -4,796 | -4,796 | -3,595 | -2,554 |
| Free Cash Flow Per Share | -571.56 | -571.56 | -436.04 | -380.06 |
| Gross Margin | 28.48% | 28.48% | -16.70% | -8.21% |
| Operating Margin | -961.08% | -961.08% | -2691.89% | -1116.22% |
| Profit Margin | -1005.43% | -1005.43% | -3487.49% | -3033.85% |
| Free Cash Flow Margin | -892.34% | -892.34% | -2066.14% | -1264.31% |
| EBITDA | -4,767 | -4,767 | -4,277 | -1,910 |
| D&A For EBITDA | 398.38 | 398.38 | 406.16 | 344.91 |
| EBIT | -5,165 | -5,165 | -4,683 | -2,255 |
| Advertising Expenses | 31.87 | 31.87 | - | - |
Source: S&P Capital IQ. Standard template.
Financial Sources.